[Ip-health] 't Hoen, Hogerzeil, Quick and Sillo in the Journal of Public Health Policy- A quiet revolution in global public health: The World Health Organization’s Prequalification of Medicines Programme

Thiru Balasubramaniam thiru at keionline.org
Thu Jan 16 04:54:24 PST 2014


A quiet revolution in global public health: The World Health Organization’s
Prequalification of Medicines Programme

Ellen F M ‘t Hoena<http://www.palgrave-journals.com/jphp/journal/vaop/ncurrent/full/jphp201353a.html#aff1>,
Hans V Hogerzeilb<http://www.palgrave-journals.com/jphp/journal/vaop/ncurrent/full/jphp201353a.html#aff2>,
Jonathan D Quickc<http://www.palgrave-journals.com/jphp/journal/vaop/ncurrent/full/jphp201353a.html#aff3>,
and Hiiti B Sillod<http://www.palgrave-journals.com/jphp/journal/vaop/ncurrent/full/jphp201353a.html#aff4>

   1. a Independent Consultant, Medicines Law and Policy, Paris, 75011,
   2. b University of Groningen, 9713 AV Groningen, The Netherlands
   3. c Management Sciences for Health, Cambridge, Massachusetts 02139, USA
   4. d Tanzania Food and Drugs Authority (TFDA), P. O. Box 77150, Dar es
   Salaam, Tanzania


Problems with the quality of medicines abound in countries where regulatory
and legal oversight are weak, where medicines are unaffordable to most, and
where the official supply often fails to reach patients. Quality is
important to ensure effective treatment, to maintain patient and
health-care worker confidence in treatment, and to prevent the development
of resistance. In 2001, the WHO established the Prequalification of
Medicines Programme in response to the need to select good-quality
medicines for UN procurement. Member States of the WHO had requested its
assistance in assessing the quality of low-cost generic medicines that were
becoming increasingly available especially in treatments for HIV/AIDS. From
a public health perspective, WHO PQP’s greatest achievement is improved
quality of life-saving medicines used today by millions of people in
developing countries. Prequalification has made it possible to believe that
everyone in the world will have access to safe, effective, and affordable
medicines. Yet despite its track record and recognized importance to
health, funding for the programme remains uncertain.


More information about the Ip-health mailing list